Abstract
Objective:
To investigate the impact of obesity, weight loss and oral glucose ingestion on serum visfatin and vaspin levels in prepubertal children.
Subjects and methods:
A total of 100 prepubertal obese Caucasian children (OB) and 42 controls (C) were studied. The OB group was studied at baseline and after moderate (n=46) and extensive (n=14) body mass index (BMI) reduction by conservative treatment, undergoing body composition studies (dual-energy X-ray absorptiometry) and oral glucose tolerance tests (OGTTs). Serum visfatin and vaspin levels were studied throughout the OGTT, as were their relationships with insulin, leptin, leptin soluble receptor (sOB-R), adiponectin (total and high molecular weight), resistin, interleukin-6 (IL-6) and tumor necrosis factor-α levels at every time point.
Results:
OB had higher visfatin (P<0.001), but similar vaspin than C. BMI reduction decreased visfatin levels (P<0.001), with BMI, waist circumference and the surrogate markers of body fat (leptin and sOB-R) showing significant correlations (P<0.05) with this peptide, but not with vaspin. Visfatin and vaspin decreased during the OGTT (P<0.001). Weight reduction did not alter visfatin dynamics in the OGTT, but decreased the area under the curve (AUC) for vaspin (P<0.001), with a correlation between the AUCs for vaspin and insulin after weight loss (P<0.05). Visfatin levels were positively correlated with resistin and IL-6, after controlling for BMI and HOMA (homeostatic model assessment) index at every time point in the study.
Conclusion:
Serum visfatin, but not vaspin, levels are influenced by body fat content in obese children, whereas both adipokines are modulated by glucose intake in a BMI-dependent manner.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Körner A, Kratzsch J, Kiess W . Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525–546.
Tilg H, Moschen AR . Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008; 14: 222–231.
Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152–12162.
Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363–375.
Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF . Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010; 2: 21.
Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res 2008; 36: 625–629.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430.
Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B . Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578–1581.
Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911–2916.
Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Com 2006; 339: 430–436.
Jeong E, Youn BS, Kim DW, Kim EH, Park JW, Namkoong C et al. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J Clin Endocrinol Metab 2010; 95: 1869–1875.
von Loeffelholz C, Möhlig M, Arafat AM, Isken F, Spranger J, Mai K et al. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol 2010; 162: 507–513.
Ye Y, Hou XH, Pan XP, Lu JX, Jia WP . Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J 2009; 122: 2530–2533.
Chang HM, Lee HJ, Park HS, Isken F, Spranger J, Mai K et al. Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity 2010; 18: 2105–2110.
Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372–377.
Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006; 43: 548–549.
Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008; 16: 384–388.
Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009; 69: 858–864.
Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A . Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009; 84: 325–328.
Lee MK, Jekal Y, Im JA, Kim E, Lee SH, Park JH et al. Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification. Clin Chim Acta 2010; 411: 381–385.
Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizarraga A et al. Curvas y tablas de crecimiento (estudio longitudinal y transversal). In: Fundación F Orbegozo (ed). Patrones de crecimiento y desarrollo en España. Atlas de gráficas y tablas. Ergón: Madrid, 2004.
Kelly TL, Specker BL, Binkley T, Zemel BS, Leonard MB, Kalkwarf HJ et al. Pediatric BMD reference database for US white children. Bone 2005; 36: S5–102.
Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W . Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783–4791.
Martos-Moreno GA, Barrios V, Martínez G, Hawkins F, Argente J . Effect of weight loss on high-molecular weight adiponectin in obese children. Obesity (Silver Spring) 2010; 18: 2288–2294.
Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK . Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1986; 315: 220–224.
Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007; 92: 483–490.
Krzyzanowska K, Mittermayer F, Krugluger W, Kopp HP, Schernthaner G . Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 2006; 14: 1886–1889.
Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M . The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909–1914.
Unlütürk U, Harmanci A, Yildiz BO, Bayraktar M . Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol (Oxf) 2010; 72: 469–474.
Chang YC, Chang TJ, Lee WJ, Chuang LM . The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010; 59: 93–99.
Fain JN . Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443–477.
Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744–747.
Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, Pfister M et al. Visfatin: the link between inflammation and childhood obesity. Diabetes Care 2009; 32: e71.
Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009; 54: 1772–1777.
Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318–1327.
Cho JK, Han TK, Kang HS . Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol 2010; 108: 347–353.
González CR, Caminos JE, Vázquez MJ, Garcés MF, Cepeda LA, Angel A et al. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol 2009; 587: 3741–3750.
Acknowledgements
We thank Dr Julie A Chowen for the critical review of the manuscript. GAMM was supported by the Fondo de Investigación Sanitaria (FIS CM05/00100). This work was supported by CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III; Proyecto de Fondo de Investigación Sanitaria FIS (PI 10-747); the Fundación Endocrinología y Nutrición; Mutua Madrileña (AP2561/2008); grants from the German Research Council (DFG) KFO 152 ‘Atherobesity’ KO3512/1-1 (to AK, JK and WK), the German Diabetes Association (to AK), the Else Kröner-Fresenius Foundation (to AK) and the LARGE consortium funded by the German Ministry of Education and Research (BMBF) within the scope of the competence networks ‘Obesity’ and ‘diabetes’.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Martos-Moreno, G., Kratzsch, J., Körner, A. et al. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int J Obes 35, 1355–1362 (2011). https://doi.org/10.1038/ijo.2010.280
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2010.280
Keywords
This article is cited by
-
Fibroblast growth factor-21 and Visfatin as potential predictors for metabolic risk factors in obese children
Scientific Reports (2024)
-
Resistin and visfatin concentrations are related to central obesity and inflammation in Brazilian children
Nutrire (2018)
-
Metabolomics allows the discrimination of the pathophysiological relevance of hyperinsulinism in obese prepubertal children
International Journal of Obesity (2017)
-
Insulin resistance in prepubertal obese children correlates with sex-dependent early onset metabolomic alterations
International Journal of Obesity (2016)
-
Physiological and pathophysiological roles of NAMPT and NAD metabolism
Nature Reviews Endocrinology (2015)